Benitec Biopharma targets mid-2027 start for BB-301 pivotal trial in OPMD dysphagia
Bitget2026/10/05 12:10Benitec outlined an FDA regulatory update for BB-301, keeping its pivotal OPMD study on track to start enrollment in mid-2027. FDA discussions continue on an open-label, single-arm pivotal design; the agency requested additional data, including the company’s OPMD natural history study. Final pivotal study design is expected to be confirmed in 1Q 2027, subject to FDA review of the added information. Interim Phase 1b/2a results have not yet been presented; they will be shown as a late-breaking poster at ESGCT on Oct. 27-30, 2026. The update signals continued regulatory alignment, supporting the planned transition from early-stage testing into a pivotal program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9839296) on October 05, 2026, and is solely responsible for the information contained therein.
- Benitec outlined an FDA regulatory update for BB-301, keeping its pivotal OPMD study on track to start enrollment in mid-2027.
- FDA discussions continue on an open-label, single-arm pivotal design; the agency requested additional data, including the company’s OPMD natural history study.
- Final pivotal study design is expected to be confirmed in 1Q 2027, subject to FDA review of the added information.
- Interim Phase 1b/2a results have not yet been presented; they will be shown as a late-breaking poster at ESGCT on Oct. 27-30, 2026.
- The update signals continued regulatory alignment, supporting the planned transition from early-stage testing into a pivotal program.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
